£495.00

The 2023-2028 Outlook for Anti-Arthritic Drugs in Japan

Subjects

Price data last checked 155 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 24 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 576 days • 576 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 576 days • 1 price levels

Days at Price

Price Analysis

Most common price: £495 (576 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 576 days

Description

This study covers the latent demand outlook for anti-arthritic drugs across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 1,000 cities in Japan. For each city in question, the percent share the city is of its prefecture and of Japan as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each prefecture and city, latent demand estimates are created for anti-arthritic drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anti-arthritic drugs as including all commonly understood products falling within this broad category, such as biologics, biosimilars, corticosteroids, janus kinase (JAK) inhibitors, anti-TNF therapy, and small-molecule therapies, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Amgen, Eli Lilly and Company, F. Hoffmann-La Roche, Johnson & Johnson, and Pfizer. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BP9NZQYS
Category: Books > Subjects
Domain: Amazon UK
Release Date: 28 November 2022
Listed Since: 08 December 2022

The 2023-2028 Outlook for Anti-Arthritic Drugs in Japan

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Bioengineered Monoclonal Antibodies Protein Drugs in Japan

The 2023-2028 Outlook for Drug Delivery Products for US Zip Codes

The 2026-2031 World Outlook for High Potency APIs (HPAPIs)

The 2025-2030 World Outlook for Peripheral Neuropathy Treatments

Biologics and Biosimilars: Drug Discovery and Clinical Applications

The 2023-2028 World Outlook for Pain-Relieving Lidocaine Patches

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs for US Zip Codes

The 2023-2028 Outlook for Prefilled Syringes and Cartridges for US Zip Codes

Biosimilars and Interchangeable Biologics: Strategic Elements

The 2023-2028 Outlook for Polycarbonate Vial Adaptors for Reconstitution Drugs in the United States

The 2023 Report on Pharma Contract Sales: World Market Segmentation by City

Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs in Japan

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs in China

The 2023 Report on Transdermal Patches: World Market Segmentation by City

Biosimilars and Interchangeable Biologics: Strategic Elements

Pharmaceutical Science to Improve the Human Condition: Prix Galien 2011, Volume 1263 (Annals of the New York Academy of Sciences)

Mastering Strategic Marketing For Specialty Pharmaceuticals: A Hands-on Guide

Biosimilars and Interchangeable Biologics: Tactical Elements

Biosimilars Development Strategies: Fast to Market Approaches

Biosimilars and Interchangeable Biologics: Tactical Elements

Academic Press Biotherapeutics Formulation and Device Management

Immunogenicity of Biopharmaceuticals: VIII (Biotechnology: Pharmaceutical Aspects, VIII)

Biosimilar and Interchangeable Biologics: From Cell Line to Commercial Launch, Two Volume Set